Skip to main content

Weed, Cannabis, and How the Cannabis Industry Impacts Economic Growth and Society

As technology advances and more beneficial uses of Cannabis are discovered, the world is becoming more aware of the benefits of the cannabis industry. We look at 3 ways the cannabis industry is contributing to society and positive economic growth in regions where it has been legalized for recreational and medicinal use.


Legalizing marijuana has made it easier for people to use it for recreational purposes. Some states have even decriminalized it and have started to allow its use for medical purposes. There are many health benefits to using Cannabis, both medically and recreationally.


One of these benefits is that it helps with pain management. People who suffer from chronic pain or arthritis can benefit from smoking weed because they don’t have to rely on prescription painkillers which have been proven to be highly addictive. 


Weeds Effects Treatments & Curable Diseases


Weeds affect treatments and curable diseases by reducing symptoms such as nausea and vomiting, loss of appetite, depression, anxiety, chronic pain, insomnia, etc. Edibles are eaten and absorbed into the body through the stomach. Cannabis edibles come in two forms, those with THC and are psychoactive, and the CBD variety, which are non-psychoactive and can have therapeutic benefits and when used as part of wellness routine.


Topicals are creams or lotions that contain cannabis extract can be used to manage inflammation and relieve pain in specific areas of the body, such as joints or muscles. There are many variations of topicals and all have therapeutic benefits. Some find cannabis topicals effective for managing the symptoms of:

     1. Multiple Sclerosis

     2. Chronic Pain and Arthritis

     3. Sexual Lubricant


Cannabis is a Positive Economic Driver in States Where it is Legal.


In state governments where the cannabis industry has become legal, the legal sale of cannabis for recreational and medical use has increased the bottom line in tax revenue and added a new jobs with new skill-set requirements in local communities. Colorado’s “Green Rush” has been viewed as an economic driver in the state, with local governments and municipalities becoming involved in regulating and taxing dispensaries and cultivation facilities. 

California recently eliminated the cultivation tax and is taking another step towards stabilizing the cannabis industry in the state. Stability of the cannabis supply chain brings more jobs and much needed tax revenue to the sate while also protecting public health and safety. Stability in regulations and safety measures in packaging and labeling of cannabis products also keep cannabis products out of the hands of children.


Safety of Marijuana Dispensaries in U.S. Cities and Awareness at the State Level 


The National Institute on Drug Abuse (NIDA) has issued a new report on marijuana facts and side effects dosage. A Study of the Safety of Marijuana Dispensaries in U.S. Cities and Awareness at the State Level” was conducted by researchers from the University of California, San Francisco (UCSF). 


The study examined the relationship between marijuana use and crime in six major U.S. cities: Los Angeles, Chicago, Houston, Miami, New York City, and Philadelphia. Researchers also examined awareness about marijuana use at the state level and how these findings relate to public opinion about marijuana legalization.


The cannabis industry has made legalization gains across the U.S. over the past two years, directly contributing to the bottom line in communities where cannabis use has been legalized. Despite major changes at the federal level, States are adopting programs for safe and legal cannabis distribution that contributes to their budgets and tax base. 


The legal cannabis industry remains in the early stages of development with much infrastructure to build. Until regulations are lifted at the federal level, some of the continued indicators for positive growth and expansion will remain stunted or slowed from reaching their full potentials. 


The cannabis industry is one of the fastest-growing sectors in America, with several states legalizing the industry every year. Tens of billions of dollars are being invested into the cannabis industry annually, with many investors looking to deploy capital into the space and grow vertically integrated companies that oversee all aspects of cannabis production and marketing.


Vibe by California is a vertically integrated cannabis company and part of the rapid growth cannabis industry in America. Vibe by California owns and operates 7 cannabis dispensaries throughout California and Oregon and has recently been recognized by the Sacramento Business Journal as one of the fastest growing companies in California for 2022, and was honored for creating new jobs and business opportunities for people living throughout the State of California and beyond.


Information on this website is shared for educational purposes only.

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Consult a medical doctor before acting on any information gathered on this website, especially if you are pregnant, nursing, taking medication, or have a pre-existing or other medical condition and intend on using cannabis products to treat or manage your condition.

For further reading about using cannabis products with THC or CBD please refer to the references below.

Papers of particular interest on CBD, THC and using cannabinoids to treat pain or other medical conditions published recently have been outlined and links provided to medical studies and research available.

1.•• Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P T. 2017;42(3):180–8 (excellent review on Cannabinoids focused on pharmacology).

PubMed  PubMed Central  Google Scholar

1.•• Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018;9:1259 (excellent review on Cannabinoids and Pain).

Article  Google Scholar

1. Russo EB. Cannabinoids in the management of difficult to treat pain. There Clin Risk Manag. 2008;4(1):245–59.

CAS  Article  Google Scholar

1.Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007;556(1–3):75–83.

CAS  Article  Google Scholar

1.Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56(11):1059–68.

CAS  Article  Google Scholar

1.Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.

CAS  Article  Google Scholar

1.Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833 Published 2018 Mar 13.

Article  Google Scholar

1.Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60(1):255–66.

CAS  Article  Google Scholar

1.Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–805.

CAS  Article  Google Scholar

1.Hammell DC, Zhang LP, Ma F, , Abshire SM, McIlwrath S, Stinchcomb AL, Westlund KNet al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936–948.

CAS  Article  Google Scholar

1.Philpott HT, OʼBrien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–51.

CAS  Article  Google Scholar

1.Malfait AM, Gallily R, Sumariwalla PF, , Malik AS, Andreakos E, Mechoulam R, Feldmann Met al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561–9566.

CAS  Article  Google Scholar

1.Babalonis S, Haney M, Malcolm RJ, , Lofwall MR, Votaw VR, Sparenborg S, Walsh SLet al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017;172:9–13.

CAS  Article  Google Scholar

1.Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Res. 2019;8:F1000 Faculty Rev-234.

Article  Google Scholar

1.Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234–46.

CAS  Article  Google Scholar

1.Vermersch P, Trojano M. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. Eur Neurol. 2016;76(5–6):216–26.

CAS  Article  PubMed  Google Scholar

1.Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018;18(2):8.

Article  Google Scholar

1.Ferrè L, Nuara A, Pavan G, Radaelli M, Moiola L, Rodegher M, et al. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci. 2016;37(2):235–42.

Article  Google Scholar

1.Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207–18.

Article  Google Scholar

1.Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.

CAS  Article  Google Scholar

1.•• Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, et al. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. J Pain Symptom Manage. 2018;55(2):179–188.e1 (excellent study on Cannabinoids and Cancer Pain).

Article  Google Scholar

1.Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1–3):210–20.

CAS  Article  Google Scholar

1.Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50–2.

CAS  Article  Google Scholar

1.Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines. 2016 Sep 21;. Review.

2.Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res. Manag. 19:328–35.

Article  Google Scholar

1.Darkovska-Serafimovska M, Serafimovska T, Arsova-Sarafinovska Z, Stefanoski S, Keskovski Z, Balkanov T. Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases. J Pain Res. 2018;11:837–42.

Article  Google Scholar

1.The FDA Warning Letters and Test Results for Cannabidiol-Related Products.


1.Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders

Research paper available in PDF form for download here: fphar-08-00269

Alline C. Campos1*, Manoela V. Fogaça1, Franciele F. Scarante1, Sâmia R. L. Joca2, Amanda J. Sales2, Felipe V. Gomes3, Andreza B. Sonego1, Naielly S. Rodrigues1, IsmaelGalve-Roperh4,5 andFranciscoS.Guimarães1

1 Department of Pharmacology, Centre for Interdisciplinary Research on Applied Neurosciences (NAPNA), School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil, 2 Department of Physical and Chemical, School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil, 3 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, United States, 4 Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain, 5 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Universitario de Investigación en Neuroquímica and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.

Frontiers in Pharmacology,  published: 23 May 2017 doi: 10.3389/fphar.2017.00269